- Cytori Therapeutics (CYTX -1.5%) rated Buy with a $7 (425% upside) price target by Maxim Group.
- Sagent Pharmaceuticals (SGNT +9.2%) rated Buy with a $29 (13% upside) price target by Deutsche Bank.
- Mylan (MYL +15.6%) rated Overweight with a $70 (2% upside) price target by JP Morgan.
- Akorn (AKRX +3.7%) rated Buy with a $55 (11% upside) price target by Deutsche Bank.
- OvaScience (OVAS-OLD +1.4%) rated Outperform with a $60 (102% upside) price target by Oppenheimer.
- Impax Laboratories (IPXL +3.2%) rated Hold with a $50 (flat) price target by Deutsche Bank.
- Catamaran (CTRX) downgraded to Hold with a $61.50 (4% upside) price target by Jefferies.
- NewLink Genetics (NLNK +4.4%) downgraded to Hold with a $50 (11% downside risk) price target by Jefferies.
- Stryker (SYK +0.4%) downgraded to Underweight with a $92 (flat) price target by Barclays.